
Join to view full profile
55 Fruit StreetYaw 7b Mass General HospitalBoston, MA 02114
Phone+1 617-724-4000
Fax+1 617-643-1915
Dr. Clark is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1982
WashU MedicineClass of 1979
Certifications & Licensure
MA State Medical License 1982 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2012, 2014, 2016-2017
Clinical Trials
- Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy Start of enrollment: 2003 Mar 01
Publications & Presentations
PubMed
- 8 citationsSuccessful rechallenge with pembrolizumab after case of progressive immunotherapy-related mucocutaneous eruption (PIRME), a Stevens-Johnson syndrome-like reaction.Connie R Shi, Michael Shaughnessy, Kartik Sehgal, John R Clark, Kerry L Reynolds
International Journal of Dermatology. 2023-10-01 - 70 citationsCell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancer.Connor J O'Boyle, Giulia Siravegna, Shohreh Varmeh, Natalia Queenan, Alexa Michel
Cancer. 2022-06-01 - 21 citationsThe efficacy and safety of cardio-protective therapy in patients with 5-FU (Fluorouracil)-associated coronary vasospasm.Amna Zafar, Zsofia D Drobni, Matthew Lei, Carlos A Gongora, Thiago Quinaglia
Plos One. 2022-01-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









